Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01616862 · ClinicalTrials.gov registry record
The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis
A clinical trial of Cystic Fibrosis and Pseudomonas Aeruginosa, sponsored by Zafer Soultan.
- Completed
- Registry status
- 53
- Enrollment target
- 1
- Study location
NCT01616862: Completed study of Cystic Fibrosis and Pseudomonas Aeruginosa, sponsored by Zafer Soultan.
NCT01616862 is a study of Cystic Fibrosis and Pseudomonas Aeruginosa that has completed, run by Zafer Soultan. The registered enrollment target is 53 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01616862, a study of Cystic Fibrosis and Pseudomonas Aeruginosa, has completed, sponsored by Zafer Soultan.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
Pseudomonas aeruginosa (Pa) is the bacterium that causes one of the most consequential lung infections in people with CF. Many young children do not have Pa in their lungs but will become infected as they get older. The investigators want to learn more about how Pa is passed from person to person, especially to someone with Cystic Fibrosis (CF).
Primary Outcome
Collection of nasal and oropharyngeal swabs will be obtained from parents living with patients at enrollment and after 3 months.
Conditions Studied
Study Locations (1)
New York
- SUNY Upstate Medical University - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-08 |
What the finished NCT01616862 record still lists
NCT01616862 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (70% lower).
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 0 interventions.
NCT01616862 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01616862 about?
NCT01616862 is a clinical study titled "The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis". Pseudomonas aeruginosa (Pa) is the bacterium that causes one of the most consequential lung infections in people with CF. Many young children do not have Pa in their lungs but will become infected as they get older. The investigators want to learn more about how Pa is passed from person to person, e...
What is the current status of trial NCT01616862?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2012-02. Estimated completion is 2013-08.
What conditions does trial NCT01616862 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Pseudomonas Aeruginosa.
Who is sponsoring clinical trial NCT01616862?
This trial is sponsored by Zafer Soultan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01616862 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01616862's enrollment target sits among peer trials
53 88th of 169 higher than 82 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia